Structural Basis for Monoclonal Antibody Therapy for Transthyretin Amyloidosis
The disease of transthyretin (TTR) amyloidosis (ATTR) has been known since the 1960s, and during the past 60 or so years, there has been a sustained period of steady discoveries that have led to the current model of ATTR pathogenesis. More recent research has achieved major advances in both diagnost...
Saved in:
Main Author: | Avi Chakrabartty (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2024-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Transthyretin Amyloidosis Therapies: Guiding the Future
by: Alejandra González-Duarte
Published: (2021) -
The Structural Understanding of Transthyretin Misfolding and the Inspired Drug Approaches for the Treatment of Heart Failure Associated With Transthyretin Amyloidosis
by: Shan He, et al.
Published: (2021) -
A review of transthyretin cardiac amyloidosis
by: Jhawar Nikita, et al.
Published: (2023) -
A Clinical Case of the Hereditary Transthyretin Amyloidosis
by: E. V. Reznik, et al.
Published: (2021) -
Oxidative Stress in Transthyretin-Mediated Amyloidosis: An Exploratory Study
by: Marco Fiore, et al.
Published: (2024)